NARA Discovery
Article Details
← Back to Search Results
Journal Article

Transdermal fluocinolone acetonide loaded decorated hyalurosomes cellulose acetate/polycaprolactone nanofibers mitigated Freund’s adjuvant-induced rheumatoid arthritis in rats

Sammar Fathy ELhabal; Mohamed A. El-Nabarawi; Soha Osama Hassanin; Fatma E. Hassan; Samah S. Abbas; Sahar M. Gebril; Rofida Albash
Journal of Pharmaceutical Investigation · Vol. 55, Issue 1 · pp. 113-132 · 2025

Abstract

Purpose This study aimed to develop a transdermal delivery system for fluocinolone acetonide (FLA), a corticosteroid used in treating inflammatory conditions like rheumatoid arthritis (RA), to overcome the limitations of oral administration, such as poor solubility and bioavailability. Methods FLA-loaded PEG decorated hyalurosomes (FLA-PHs) were fabricated using ethanol injection, incorporating various Brij® surfactants and different amounts of hyaluronic acid (HA) based on a full factorial design. The impact of independent variables, HA amount (mg) (X 1 ) and Brij type (X 2 ) were inspected for entrapment efficiency (EE%), particle size (PS), and zeta potential (ZP). The optimum FLA-PHs were then incorporated into ε-polycaprolactone (PCL) and cellulose acetate (CA) nanofibers to enhance sustained transdermal delivery (FLA-NFs). Results The optimum FLA-PHs exhibited EE% of 83.58 ± 0.69%, PS of 169.00 ± 1.41 nm, and ZP of -22.90 ± 0.14 mV. Morphological assessment of FLA-NFs showed promising results in terms of surface roughness. In a Freund-induced rat model of adjuvant-induced arthritis, transdermal treatment with FLA-NFs significantly improved joint histopathological analyses. Furthermore, it suppressed inflammatory markers such as mTORC1, TNF-α, and NF-κB while upregulating TRIM24 and the anti-inflammatory IL-10. Conclusion FLA-NFs present a promising strategy for enhancing the transdermal delivery of FLA for managing RA, offering potential improvements in efficacy and reduced systemic side effects compared to conventional oral administration.

Bibliographic Information

JournalJournal of Pharmaceutical Investigation
PublisherSpringer
Publication Date2025-01-01
Publication Year2025
Volume55
Issue1
Pages113-132
Document TypeJournal Article
Print ISSN2093-5552
eISSN2093-6214
DOI10.1007/s40005-024-00693-8

Access Information

NARA Access Coverage2012-01-01~Current
Journal Homepagehttps://www.springer.com/journal/40005
Publisher PageOpen Publisher Page
Full-text access depends on NARA's subscribed coverage and institutional access.